Psirelax is an herbal topical medication indicated for the treatment ofpatients with psoriasis. Its efficacy was determined in an open-labelstudy in 22 patients (15 men, 7 women) with a mean age of 48.9±11.8years suffering from chronic plaque psoriasis. The patients weretreated by application of Psirelax twice a day for a period of 4 weeks.Clinical assessment was performed using the Psoriasis Area andSeverity Index (PASI) and the Beer-Sheva Psoriasis Severity Score(BPSS). The results shows that Psirelax was well tolerated and thereno local or systemic side effects. There was 59% reduction in PASI,from a mean of 5.9 ± 4.0 before treatment to 2.4 ± 2.4 after treatment(p<0.001). In 8 patients (36%) PASI decreased in more than 75%(PASI75). In 16 patients (73%) PASI decreased in more than 50%(PASI50). Application of Psirelax was associated with a decrease indisease severity, as assessed by the patients and physicians. It isconcluded that Psirelax treatment was well tolerated in patients withchronic plaque psoriasis